Preliminary communication: Urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease

✍ Scribed by Ryuji Sakakibara; Tomoyuki Uchiyama; Mitsuharu Yoshiyama; Tomoyuki Yamanishi; Takamichi Hattori

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 113 KB
• Volume: 24
• Category: Article
• ISSN: 0733-2467
• DOI: 10.1002/nau.20102

✦ Synopsis

Abstract

Background and Aims

Donepezil hydrochloride, a central cholinergic drug, is widely used for improving cognitive decline in Alzheimer's disease (AD). We investigated whether donepezil might affect the lower urinary tract (LUT) function in AD.

Methods

Alzheimer's Disease Assessment Scale cognitive subscale (ADAS‐cog) (0–70, increase as impairment), urinary questionnaire, and electromyography (EMG)‐cystometry were performed in eight patients with AD before and after treatment with 5 mg/day of donepezil.

Results

The first assessment (before donepezil) showed moderate cognitive decline in the patients as a mean ADAS‐cog score of 27.0 (range: 17–35) (normal < 15). Seven patients had urinary symptoms including urinary urgency incontinence in five.EMG‐cystometry revealed neurogenic detrusor overactivity in seven with a mean detrusor pressure of 44.9 cmH~2~O (20–101), mean bladder capacity of 202 ml (20–412), and post‐void residuals in none. The second assessment (3 months after donepezil) showed a decrease in the ADAS‐cog score to 23.3 (11–35) though without statistical significance. Urinary incontinence disappeared in one and none had a new onset of incontinence. EMG‐cystometry revealed an increase in the detrusor pressure on overactivity to 54.1 cmH~2~O (20–122), but also an increase in the bladder capacity to 234 ml (80–400), and post‐void residuals in one (40 ml).

Conclusion

Although the number of our patients was small, it seems possibly that donepezil could ameliorate cognitive function without serious adverse effects on the LUT function in patients with AD. © 2004 Wiley‐Liss, Inc.